Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
GNI Group ( (JP:2160) ) just unveiled an announcement.
GNI Group Ltd. announced an amendment to its Consolidated Financial Results for FY2024 due to a tax review of its subsidiary, GNI USA, Inc. The corrections involve adjustments to profit and loss figures, reflecting a minor improvement in profit attributable to owners of the parent and comprehensive income. These changes highlight the company’s ongoing financial adjustments and could impact stakeholder perceptions of its financial health.
More about GNI Group
GNI Group Ltd. operates in the biotechnology and pharmaceutical industry, focusing on developing and commercializing innovative therapies. The company is listed on the TSE Growth market and has a global presence with subsidiaries, including GNI USA, Inc.
Average Trading Volume: 42
Technical Sentiment Consensus Rating: Sell
Current Market Cap: €1B
For a thorough assessment of 2160 stock, go to TipRanks’ Stock Analysis page.